Q3 2025 STERIS plc Earnings Call Transcript
Key Points
- Steris PLC (STE) reported a 6% growth in total revenue for the third quarter, driven by volume and price increases.
- Gross margin improved by 90 basis points to 44.6%, indicating effective management of costs and pricing strategies.
- Adjusted earnings per diluted share increased by 11% to $2.32, showcasing strong earnings growth.
- Free cash flow for the first nine months reached $588 million, on track to meet the full-year guidance of $700 million.
- Healthcare segment saw a 7% growth in constant currency organic revenue, driven by strong recurring revenue streams and market share gains.
- EBIT margin decreased by 10 basis points to 23.3% due to litigation expenses and increased healthcare benefit costs.
- Healthcare capital equipment revenue declined by 5% due to shipment delays, impacting overall revenue expectations.
- Currency rate changes negatively impacted both revenue and profit, leading to a revised earnings guidance.
- Legal expenses related to the ethylene oxide trial increased significantly, adding financial pressure.
- Life Sciences Group experienced a 1% decline in constant currency organic revenue, affected by a drop in capital equipment revenue.
Good day and welcome to the Steris PLC third quarter 2025 conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Ms. Julie Winter. Please go ahead.
Thank you, Jack, and good morning, everyone. As usual, speaking on today's call will be Mike Tokich, our Senior Vice President and CFO, and Dan Carestio, our President and CEO. I do have a few words of caution before we open for comments.
This webcast contains time sensitive information and is accurate only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of Steris is strictly prohibited.
Some of the statements made during this review are or may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, those risk factors described in Steris's securities filings.
The company
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
